NULLAOSTA ALL’AVVIO DELLA SPERIMENTAZIONE DENOMINATA TAS6417-301 “RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE 3, GLOBAL MULTI-CENTER TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ZIPALERTINIB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE, IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS”, DA EFFETTUARSI PRESSO L’U.O. ONCOLOGIA DI RAVENNA E CONTESTUALE APPROVAZIONE DELLA CONVENZIONE PER SPERIMENTAZIONE CLINICA.